Core Insights - P3 Health Partners Inc. reported its financial results for Q4 and full year 2025, indicating a strategic repositioning of the business and a clear path to profitability for 2026 with an expected $10 million adjusted EBITDA midpoint [1][2]. Financial Performance Fourth Quarter 2025 Results - Total revenue reached $384.8 million, up from $370.7 million in Q4 2024, with capitated revenue PMPM improving by 9% year-over-year to $1,060 [3]. - The company reported a net loss of $165.7 million compared to a net loss of $129.1 million in the same quarter of the previous year [3]. - Adjusted EBITDA loss was $76.1 million, worsening from a loss of $67.6 million in Q4 2024 [3]. Full-Year 2025 Results - Total revenue for the year was $1.46 billion, down from $1.50 billion in 2024, with capitated revenue PMPM improving by 5% year-over-year to $1,026 [3]. - The net loss for the year was $323.1 million, compared to a net loss of $310.4 million in 2024 [3]. - Adjusted EBITDA loss for the year was $161.3 million, an improvement from a loss of $167.2 million in 2024 [4]. 2026 Guidance - The company expects adjusted EBITDA to range from negative $20 million to positive $40 million, with a midpoint of $10 million, indicating a projected $170 million year-over-year improvement [4]. - At-risk membership is anticipated to be between 107,000 and 117,000, with total revenues expected to be between $1.5 billion and $1.7 billion [4]. Strategic Initiatives - The CEO highlighted the strengthening of contract economics and provider alignment as key factors in the company's progress, emphasizing a deliberate approach to growth that enhances long-term earnings potential [2]. - The company aims to improve its operational foundation and provider relationships to support its transition to profitability [2].

Core Insights - McKesson Corporation announced the retirement of Britt Vitalone, the current CFO, after a 20-year career, with Kenny Cheung set to succeed him as CFO effective May 29, 2026 [1] - Vitalone will continue to support McKesson as a strategic advisor during the transition and the planned separation of its Medical Surgical Solutions segment [1] - The leadership transition occurs as McKesson reports strong financial performance, including record revenue and adjusted operating profit in its third quarter earnings [1] Leadership Transition - Britt Vitalone has served as CFO for over eight years and has been pivotal in enhancing the company's financial performance and shareholder engagement [1] - Kenny Cheung joins from Sysco, where he was CFO, overseeing global financial planning and analysis [1] Financial Performance - McKesson's third quarter results indicate continued momentum in its oncology and multispecialty services, alongside strength in core distribution businesses [1] - The company is focused on executing its strategy and delivering strong performance amid the leadership change [1]

Core Insights - Kenvue reported a fourth quarter diluted EPS of $0.17 and an adjusted diluted EPS of $0.27, reflecting a year-over-year increase from $0.15 and $0.26 respectively [1][2] - The company experienced a 3.2% increase in net sales for Q4 2025, driven by a 1.2% organic sales growth and a 2.1% foreign currency benefit [1][2] - For the full year 2025, net sales decreased by 2.1%, primarily due to a 2.2% decline in organic sales, partially offset by a 0.2% foreign currency benefit [2] Financial Performance - Q4 2025 operating income margin improved to 14.2% from 13.2% in the prior year, while adjusted operating income margin rose to 19.9% from 19.2% [1][2] - Full year 2025 gross profit margin expanded by 10 basis points to 58.1%, while adjusted gross profit margin declined by 20 basis points to 60.2% [2] - Net cash flows from operating activities for the full year 2025 were $2.2 billion, an increase from $1.8 billion in the prior year [2][7] Business Segment Results - In Q4 2025, the Self Care segment saw a 1.5% increase in net sales, while the Skin Health and Beauty segment increased by 2.9%, and the Essential Health segment grew by 6.1% [1][5] - Organic sales in the Self Care segment declined by 1.2%, driven by a 3.1% volume decrease, while the Essential Health segment achieved a 4.2% organic sales growth [1][5] Proposed Transaction - Kenvue has entered into a definitive merger agreement with Kimberly-Clark, with the transaction expected to close in the second half of 2026, pending regulatory approvals [2][4] - Shareholders of both companies have overwhelmingly approved the necessary proposals for the acquisition [2][4] Cash and Debt Position - As of December 28, 2025, Kenvue reported total cash and cash equivalents of $1.1 billion and total debt of $8.5 billion [2][7] - Free cash flow for the full year 2025 increased to $1.7 billion from $1.3 billion in the prior year [2][7]

Core Points - Henry Schein, Inc. will present at Piper Sandler's Healthcare Conference on December 2, 2025, at 9:00 a.m. Eastern time [1] - The company is the largest provider of health care solutions to office-based dental and medical practitioners [1][4] - Henry Schein's sales reached $12.7 billion in 2024, with a compound annual growth rate of approximately 11.2% since becoming public in 1995 [4] Company Overview - Henry Schein operates a centralized and automated distribution network, offering over 300,000 branded and corporate brand products [3] - The company employs more than 25,000 Team Schein Members globally, serving over 1 million customers with more than 300 solutions [2] - Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories [4]

Core Insights - Essity has partnered with Accenture and Microsoft to enhance the adoption of AI agents aimed at improving productivity and growth through increased business agility [1][2][3] Collaboration Details - The collaboration will take place at Essity's AI Centre of Excellence, where Accenture's cloud, data, and AI experts will utilize Microsoft's technologies, including Azure and Power Platform, to create a flexible cloud-based platform for AI capabilities [3][4] - The initial phase will focus on enhancing procurement and finance operations, with plans to scale AI across other business processes in the long term [4][5] Strategic Goals - The partnership aims to generate value for consumers, customers, and employees by embedding data and AI into core business processes, ensuring ethical and compliant use aligned with Essity's core values [5] - Essity's ambition is to become a pioneering company in the hygiene and health sector by reinventing key business processes with AI [5][6] Company Background - Essity is a global hygiene and health company with net sales of approximately SEK 146 billion (EUR 13 billion) in 2024 and employs around 36,000 people [7]

Core Insights - Johnson & Johnson will participate in the Citi's 2025 Global Healthcare Conference on December 3, 2025, with management engaging in a Fireside Chat at 11:15 a.m. Eastern Time [1] - A live audio webcast of the presentation will be available on Johnson & Johnson's Investor Relations website, with an archived edition accessible later that day [2] - The company also announced its participation in the 7th Annual Wolfe Research Healthcare Conference on November 17, 2025, with a Fireside Chat scheduled for 10:40 a.m. Eastern Time [3] Company Developments - Johnson & Johnson announced its intent to separate its Orthopaedics business to enhance strategic and operational focus, aiming to drive value for stakeholders and strengthen its position in Innovative Medicine and MedTech [6]

Core Insights - Johnson & Johnson will participate in the 7th Annual Wolfe Research Healthcare Conference on November 17, 2025, with a Fireside Chat scheduled at 10:40 a.m. Eastern Time [1][2] Company Developments - Johnson & Johnson announced its intent to separate its Orthopaedics business to enhance strategic and operational focus, aiming to drive value for stakeholders and strengthen its position in Innovative Medicine and MedTech [6] - The company reported strong performance in Q3 2025, attributing growth to the strength of its portfolio and progress across its pipeline, while raising its sales outlook for 2025 [7]